Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07660640
Enrolling by invitation Observational

Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

NCT07660640 · tracked via the Priya Life Science USA tracker
Sponsor
Perceive Biotherapeutics, Inc
Phase
Observational
Started
2026-03-03
Last updated
2026-06-22

Condition(s) studied

Age-Related Macular Degeneration (AMD)Non-Neovascular Age-Related Macular Degeneration

Investigational drug(s) / intervention(s)

observational studyVOY-101 →

observational study: No intervention - observational study

VOY-101: One-time intravitreal injection of VOY-101.

Study summary

Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Have received an injection of VOY-101 and exited either the PBI-AMD-001 or PBI-AMD-002 Phase 1/2a study of VOY-101. 2. Are willing and able to understand and provide informed consent. Exclusion Criteria: There are no exclusion criteria for this study

Primary outcome measure(s)

  • Frequency of ocular and systemic VOY-101 related AEs — 3 years
    Frequency of ocular and systemic VOY-101 related AEs (serious \[SAEs\] and treatment-emergent non-serious adverse events \[TEAEs\]).

Trial sites (4)

FacilityCityRegionStatus
Ophthalmic Consultants of Boston Boston Massachusetts
Retina Consultants of Texas Bellaire Texas
University of Utah Salt Lake City Utah
Sourasky Medical Center - Ichilov Tel Aviv Israel

More Perceive Biotherapeutics, Inc. trials in the USA

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration Active, not recruiting

Other trials for the same condition

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections Enrolling by invitation
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration Active, not recruiting
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07660640 on ClinicalTrials.gov ↗ ← All trials in the USA